Cargando…
Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107-5111.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905710/ https://www.ncbi.nlm.nih.gov/pubmed/35238914 http://dx.doi.org/10.1182/bloodadvances.2022007186 |
| _version_ | 1784665249531559936 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8905710 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89057102022-03-09 Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107-5111. Blood Adv Erratum American Society of Hematology 2022-03-02 /pmc/articles/PMC8905710/ /pubmed/35238914 http://dx.doi.org/10.1182/bloodadvances.2022007186 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| spellingShingle | Erratum Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107-5111. |
| title | Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107-5111. |
| title_full | Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107-5111. |
| title_fullStr | Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107-5111. |
| title_full_unstemmed | Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107-5111. |
| title_short | Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107-5111. |
| title_sort | tiong is, dillon r, ivey a, et al. clinical impact of npm1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. blood adv. 2021;5(23):5107-5111. |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905710/ https://www.ncbi.nlm.nih.gov/pubmed/35238914 http://dx.doi.org/10.1182/bloodadvances.2022007186 |